Hims & Hers, Zealand, and Roche fall: Why weight loss drug stocks are down today
Several weight loss drug stocks are sliding today as pharmaceutical companies battle for dominance in the booming GLP-1 ...
NVO Stock Slips 4% as Roche Inks Obesity Drug Deal With Zealand
With Roche's latest deal, a new contender enters the obesity space, which could threaten NVO and LLY's dominance in the ...
Medical Marketing & Media16h
Roche strikes $5.3B obesity treatment deal with Zealand Pharma
Roche is doubling down on competing for a slice of the rapidly growing GLP-1 pie. The Swiss pharma giant announced a deal worth up to $5.3 billion on Wednesday with Danish drugmaker Zealand Pharma to ...
Pharma Stock Roundup: RHHBY Obesity Drug Rights Buyout, NVO Pipeline Update
NVO reports disappointing data from a phase III study on a novel obesity candidate, CagriSema. RHHBY buys rights to obesity candidate from Zealand Pharma.
AbbVie Is Preparing To Challenge Eli Lilly And Novo Nordisk
AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.
Devdiscourse10h
A Global Health System at a Crossroads: Innovations, Challenges, and Leadership Changes
Current health news highlights include Apollo Hospitals' AI investments to alleviate staff workload, Dr. Mehmet Oz's Medicare ...
The Dow drops almost 500 points and the S&P 500 enters a correction as Trump tariffs rattle markets
Stocks entered a correction on Thursday as the S&P 500 index fell 10% from its recent peak after President Donald Trump ...
European Stocks Rally On Ukraine Deal Hopes
European stocks rebounded yesterday after four days of declines as Ukraine accepted a ceasefire proposal brokered ...
Analysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF) and Beam Therapeutics (BEAM)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Roche Holding AG (RHHVF – Research Report) ...